|Articles|May 4, 2012

Research Shows Most Clinical Trials are Too Small and Missing Data

Author(s)Kayda Norman

New research released has indicated that the majority of clinical trials are small and missing significant data. This has come to light after analyzing over 95,000 trials registered on ClinicalTrials.gov, despite the 2004 mandate that all published clinical studies must be registered on the online database.

Some studies (7%) even failed to mention the trial’s purpose, and 4% didn’t state how man volunteers were taking part in the study. Those that did give volunteer numbers showed that 62% of trials from 2007 to 2010 had 100 or fewer participants. Nevertheless, the number of registered studies has increased (due to the new law in 2004) with 40,970 studies registered from October 2007 to September 2010 vs. 28,881 from 2004-2007.

Of the trials analyzed, three specific areas were focused on including oncology, cardiology, and mental illness (totaling 79,413 studies). Cancer trials in particular were shown to be the least stringent in following medical guidelines. For example, 65% of oncology trials failed to randomize patients.

"We think expert groups need to start scrutinizing the database more and really examine the quality of the trials one by one," report author Robert Califf, MD, Vice Chancellor for Clinical and Translational Research at Duke University, told healthday.com. "For the first time, we have a chance to look at the entire universe [of clinical research] and we can see that we can do better."

Do you agree with the results of this study? How can companies improve clinical research?


Related to this article

© photon_photo - © photon_photo - stock.adobe.com
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Where AI Governance in Clinical Development Falls Short
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.